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Introduction and context {#s01}
========================

Atherosclerotic cardiovascular disease (CVD), including coronary heart disease (CHD), stroke and peripheral arterial disease, is the leading cause of death globally. Abnormal blood lipids (dyslipidemia), smoking, and high blood pressure are responsible for more than 75% of cases. But of nine independent risk factors for myocardial infarction (MI), dyslipidemia is associated with the highest population-attributable risk \[[@bib-001]\]. In addition, the evidence from randomized controlled trials (RCTs) supporting the importance of aggressive low-density lipoprotein (LDL)-cholesterol lowering is the most robust of various CVD therapies \[[@bib-002]\], particularly for statins \[[@bib-003]\].

However, despite use of proven therapies, event rates in RCTs remain relatively high, underpinning the quest for novel treatments. In addition to testing new approaches to LDL-cholesterol lowering, there has been a major focus on treatments that can favorably influence high-density lipoprotein (HDL)-cholesterol and triglyceride concentrations. Such therapies may have particular benefit in people with diabetes, which is associated with both a higher case-fatality rate after acute coronary events and a poorer long-term prognosis \[[@bib-004]\].

Recent advances {#s02}
===============

Low-density lipoprotein cholesterol {#s02_1}
-----------------------------------

### Statins {#s02_1_1}

There is a clear linear relationship between the degree of LDL-cholesterol lowering achieved with statins and benefits, with a 10% and 21% reduction in all-cause mortality and major vascular events, respectively, per 1.0 mmol/L reduction in LDL-cholesterol \[[@bib-003]\]. This is further supported by data showing superiority of more, compared to less, intensive LDL-cholesterol lowering \[[@bib-003]\].

Benefits have been found in people with CHD, stroke, or diabetes and those who are apparently healthy. More recently, another potential use of statins arises from a meta-analysis showing a decrease in peri-procedural surrogates of myocardial injury following percutaneous coronary interventions \[[@bib-005]\].

Meta-analyses have also re-affirmed the overall safety of statins, with no significant increase in non-vascular mortality nor in incident or fatal cancer \[[@bib-003]\].

Statins are generally well tolerated apart from myalgia, although its frequency is higher in clinical use than in RCTs. Recent observational data in over 2 million individuals have also shown that acute renal failure may be a dose-related side effect of statins, although it has a very low incidence. Treatment of approximately 1700 persons over 12 weeks with high-dose, compared to low-dose, statin therapy was associated with one associated hospitalization \[[@bib-006]\]. Previous meta-analysis of RCTs has shown that one incident case of new type 2 diabetes might occur for every 255 individuals treated for 2 years with statins \[[@bib-007]\]. Although warnings have been issued concerning possible impairment of cognition by statins, this was based on less robust observational data. Some major outstanding questions remain concerning statins. One is their time of commencement in those who are apparently healthy.

An important analysis has compared CHD risk reduction in subjects with genotypes that impact on LDL-cholesterol concentrations throughout life and in RCTs of statins with follow-up of approximately 4-5 years \[[@bib-008]\]. There was approximately 3-fold greater reduction in CVD death, non-fatal MI, and coronary revascularization (when the latter could be ascertained) per 1 mmol/L lower LDL-cholesterol concentrations with lifetime exposure compared to that seen in RCTs.

How might appropriate candidates for early treatment be selected?

The early stages of atherosclerosis are present in many asymptomatic younger adults in the second and third decades of life \[[@bib-009]\]. Earlier commencement of statins would gain greater clinical traction were cost-effective, non-invasive means available to identify those at highest risk. Among possible indicators, a significant family history of premature CHD has the most evidence and is supported by guidelines \[[@bib-010]\]. Quantification of coronary artery calcification in intermediate-risk patients \[[@bib-011]\] is already used by many clinicians. Ideally the value of imaging and blood analytes would be tested in RCTs comparing outcomes after biomarker or image-guided screening with usual practice without such screening. However, such RCTs would have logistic difficulties and are unlikely to be undertaken.

Despite the extremely robust evidence base supporting the use of statins, other LDL-cholesterol lowering therapies are needed. This is because the LDL-cholesterol target suggested in guidelines, currently 1.8-2.0 mmol/L in highest-risk patients, is often not achieved. Patients may be intolerant of statins. Finally, in addition to the high "residual risk" despite reaching the recommended LDL-cholesterol target, more aggressive therapy may be needed in special conditions. These include familial hypercholesterolemia (FH), when LDL-cholesterol concentrations are typically above 2.6 mmol/L despite statins, and those with genetic elevation in lipoprotein(a). Indeed, FH is now thought to affect about 1 in 200 individuals, making it the most common genetically transmitted disease \[[@bib-012]\]. The potential use of combination LDL-cholesterol lowering therapy is supported by modelling showing a greater impact of a further reduction of LDL cholesterol by 1 mmol/L on top of a starting dose of a statin compared simply to doubling the statin dose, which further reduces LDL cholesterol by only about 6% \[[@bib-013]\].

Ezetimibe {#s03}
=========

Ezetimibe targets the NPCILI receptor in intestinal cells to inhibit absorption of cholesterol and plant sterols \[[@bib-014]\]. Ezetimibe lowers LDL cholesterol by about 20% and its combination is rational because statins increase cholesterol absorption \[[@bib-015]\].

Initial trials investigating effects of ezetimibe on surrogate endpoints were somewhat disappointing. However, further important evidence will be provided by the IMPROVE-IT study, which is testing whether combination therapy with ezetimibe and simvastatin given to patients after acute coronary syndromes and with a target LDL cholesterol of approximately 1.4 mmol/L reduces events compared to simvastatin alone with the present usual target of 1.8 mmol/L \[[@bib-016]\]. The trial will have a very large number of events and also provide important safety data concerning very low LDL-cholesterol levels. Until its results are available, ezetimibe is often given to subjects who fail to achieve target LDL-cholesterol levels, particularly those with higher baseline LDL-cholesterol concentrations or with diabetes.

Long-acting niacin formulations {#s04}
===============================

Many years ago, niacin was shown to be beneficial as monotherapy. In addition to lowering LDL cholesterol and triglycerides by about 15% and 40%, respectively, HDL-cholesterol concentrations are increased by 20%-25% and lipoprotein(a) (Lp\[a\]) decreased by 25%. However, side effects, particularly flushing, have limited its use. It had been hoped that longer-acting formulations, possibly associated with prostaglandin inhibition, might increase its tolerability.

Two recent trials of adding niacin to a statin in patients with CVD and possibly diabetes have disappointed.

The AIM-HIGH trial \[[@bib-017]\] in 3300 subjects with vascular disease and atherogenic dyslipidemia was very likely underpowered but showed no further reduction in vascular events with niacin-statin combination. However, on-treatment HDL and LDL concentration differences were only +4 and −5 mg/dL, respectively. More recently, the much larger HPS2-THRIVE trial \[[@bib-018]\] in approximately 27,000 patients with vascular disease and/or diabetes also showed no further reduction in events beyond statin therapy alone. However, on-treatment differences in lipid subfractions between the randomized limbs were again relatively small. In addition, in HPS-2 THRIVE, there were more side effects in those patients randomized to niacin-laropiprant, the prostaglandin inhibitor included in this formulation. Full results are still to be formally published.

Bile acid sequestrants {#s05}
======================

Non-absorbable anion-exchange resins such as cholestyramine, nonspecifically bind cholesterol-rich bile acids in the gut, increasing the breakdown of cholesterol and fecal excretion of bile salts by interrupting the enterohepatic circulation. They have a moderate effect in lowering LDL cholesterol by 10%-20% and were used particularly when statins could not be taken. They may increase triglyceride levels. A significant reduction in CHD events with use of cholestyramine in primary prevention was demonstrated many years ago in the LRC-CPPT \[[@bib-019]\] and in smaller secondary prevention trials. However, upper and lower gastrointestinal side effects are relatively common, and the use of resins has been largely supplanted by other agents.

PCSK9 inhibitors {#s06}
================

Agents that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are arguably the most appealing of the new therapeutic agents for lowering LDL cholesterol. Their use is plausible because of known biology \[[@bib-020]\]. PCSK9 regulates plasma concentrations of LDL cholesterol by interacting with LDL receptors on liver cells. After binding to an LDL receptor, PCSK9 directs it to lysosomal degradation. Thus, it inhibits recycling of the receptor to the surface of the hepatocyte and delays catabolism of LDL particles. Co-administration with statins also has a sound rationale because statins and some other lipid-modifying drugs upregulate PCSK9. This probably explains the quite modest dose-related increase in LDL-cholesterol lowering with statins.

Gain-in-function \[[@bib-021]\] and nonsense mutations \[[@bib-022]\] in PCSK9 are reflected in different CHD event rates. It is also relevant that homozygous individuals with complete absence of PCSK9 and very low levels or LDL cholesterol of about 0.3 mmol/L have been reported to be healthy \[[@bib-023]\].

PCSK9 inhibitors tested to date are monoclonal antibodies that reduce LDL-cholesterol concentrations by about 50% and thus far have been well tolerated in a number of trials \[[@bib-024]\]. Large phase III clinical trials are ongoing. The present agents require subcutaneous administration and have usually been given every 2 to 4 weeks. Approaches based on RNA interference and antisense therapy are under development, and the development of small molecules offers the future possibility of oral administration. Further safety data must also be obtained, partly because PCSK9 is expressed in tissues other than the liver. Present compounds can also potentially induce autoantibodies.

Antisense oligonucleotides {#s07}
==========================

Mipomersen is an antisense oligonucleotide that binds to messenger RNA to prevent its translation and formation of apolipoprotein-B \[[@bib-020]\]. This in turn decreases formation of apoB-containing lipoproteins, including LDL cholesterol. Mipomersen can also decrease Lp(a) concentrations. Despite effective reduction in LDL-cholesterol levels of 40%-50%, side effects, including injection-site reactions in almost all, influenza-like illness in many, and hepatic steatosis with elevation in liver enzymes in up to 15% of patients, are problematic. However, mipomersen has recently been approved in the US for use in patients with homozygous familial hypercholesterolemia \[[@bib-025]\] in whom need for apheresis may be minimized.

MTP inhibition {#s08}
==============

Lomitapide is the prototype microsomal triglyceride transfer protein (MTP) inhibitor. Such agents inhibit the transfer of triglyceride to apoB-48 or apoB-100 in intestinal and liver cells, respectively. Therefore, they decrease formation of chylomicrons and very-low-density lipoprotein (VLDL) in these two sites \[[@bib-019],[@bib-026]\]. Inhibition of VLDL then leads to inhibition of LDL formation. Again, side effects have limited use of lomitapide, particularly increased stool frequency, hepatic steatosis, and increase in serum transaminase levels. Lomitapide has also recently been approved in the US for use in homozygous familial hypercholsterolemia. This class of compounds could have greater clinical use with further investigation of intestine-specific inhibitors.

Thyromimetics {#s09}
=============

Hyperthyroidism is associated with decrease in plasma cholesterol concentrations. Dextrothyroxin was investigated in the Coronary Drug Project and other studies many years ago. However, adverse events, including hyperthyroidism, led to it being abandoned. Investigation of newer agents, which may be safer and potentially reduce atherogenic lipoproteins and increase reverse cholesterol transport, is ongoing.

High-density lipoprotein cholesterol and triglycerides {#s10}
======================================================

HDL cholesterol has many anti-atherogenic effects. Basic studies have shown the importance of reverse cholesterol transport from the atherosclerotic plaque back to the liver. Indeed, a robust measure of efflux capacity was associated with coronary artery disease endpoints in fully adjusted models, which included both HDL cholesterol or apolipoproteinA-1 \[[@bib-027]\]. HDL cholesterol is also anti-inflammatory and inhibits monocyte adhesion to the endothelium, inhibits LDL oxidation prior to its incorporation with macrophages in foam cells, inhibits thrombosis, and improves endothelial function and insulin sensitivity. In addition, strong epidemiologic data show an inverse exponential association between usual HDL-cholesterol levels and CHD risk \[[@bib-028]\]. This inverse association is maintained in patients already receiving statins, even with low LDL-cholesterol concentrations. Low HDL-cholesterol and/or elevated triglyceride concentrations, together with shift to the small dense LDL phenotype, is also the most prevalent lipid disorder in people with type 2 diabetes or the metabolic syndrome.

However, the importance of increasing HDL-cholesterol concentrations has been challenged recently. Gene variants that increase HDL-cholesterol concentrations and have no effect on LDL-cholesterol concentrations do not usually protect against CVD \[[@bib-029]\]. Particularly, published RCTs that sought to test whether increasing HDL cholesterol is protective have been disappointing \[[@bib-030]\].

Fibrates {#s11}
========

Fibrates are weak agonists of peroxisome proliferator-activated receptor alpha (PPAR-α). A significant reduction in CHD events with gemfibrozil was shown in the Helsinki Heart Study \[[@bib-031]\] and was associated with a small reduction in LDL cholesterol, a larger reduction in triglycerides, and more than 10% increase in HDL cholesterol. In VA-HIT \[[@bib-032]\], gemfibrozil was also shown to reduce CVD events in post-MI patients with low HDL-cholesterol levels.

The FIELD \[[@bib-033]\] and ACCORD \[[@bib-034]\] RCTs were large placebo-controlled studies of fenofibrate in people with diabetes. Statins were not mandated in FIELD, but were in ACCORD. Both trials showed no reduction in macrovascular events, such as related to CHD. However, microvascular events, including retinal and renal outcomes and autonomic neuropathy, were significantly reduced. In addition, a meta-analysis has shown a reduction in macrovascular events in those with low HDL-cholesterol (≤0.9 mmol/L) and high triglyceride (≥2.3 mmol/L) concentrations \[[@bib-035]\], supporting a particular role of fibrates in this context. It should also be noted that fenofibrate was associated with only a very small, if any, increase in HDL-cholesterol concentration in these trials, and the agent can possibly be regarded as impacting particularly on triglycerides, which are decreased by 30% or more, and other mechanisms, such as coagulation and inflammation. If fibrates are used, fenofibrate is the agent of choice from this class and, unlike other fibrates, it has no pharmacokinetic interaction with statins.

CETP inhibitors {#s12}
===============

Cholesteryl ester transfer protein (CETP) is associated with the transfer of cholesterol between anti-atherogenic apolipoprotein A-containing particles and pro-atherogenic apolipoprotein B particles \[[@bib-036]\]. CETP inhibition appeared to offer great potential for the treatment of dyslipidemias. However, completed large-scale trials have thus far been disappointing.

The ILLUMINATE trial \[[@bib-037]\] evaluated torcetrapib, which increased HDL cholesterol by approximately 60% and decreased LDL cholesterol by approximately 25% on the background of a statin. ILLUMINATE was terminated prematurely because of an increase in all-cause mortality and cardiovascular events in those randomized to torcetrapib. In addition, a significant increase in systolic blood pressure of 5-6 mm Hg was noted. Untoward effects were most likely related to off-target toxicity with an increase in levels of aldosterone and other vasoactive hormones such as cortisol. Torcetrapib also has other adverse effects by reducing expression of endothelial nitric oxide (NO) synthase and increasing expression of endothelin-I.

Dalcetrapib had little effect on LDL cholesterol but increased HDL cholesterol by approximately 30%. The dal-OUTCOMES trial \[[@bib-038]\] was terminated early on the grounds of futility. In dal-OUTCOMES, dalcetrapib also was associated with a much smaller but still significant increase in blood pressure and in C-reactive protein levels, the latter a marker of inflammation. Both torectrapib and dalcetrapib have been withdrawn from development because of these trial results.

Large trials of the very potent CETP inhibitors anacetrapib in 30,000 subjects with occlusive arterial disease \[[@bib-039]\] and evacetrapib in 11,000 subjects at high CVD risk \[[@bib-040]\] are ongoing and their results are awaited with great interest. Initial data have shown that these agents, on a background of statin use, have very powerful and potentially beneficial effects on both HDL cholesterol (over 100% increase) and LDL cholesterol (about 50% decrease) and no effect on blood pressure. It is of interest that CETP gene variants impact on CHD event rates \[[@bib-041]\] but whether or not this reflects only the associated changes in HDL-cholesterol concentrations is unclear because such genetic variants are typically associated also with altered LDL-cholesterol concentrations.

RCTs ultimately test an intervention rather than operative mechanisms. A major outstanding question is whether it is HDL functionality rather than simply the number of HDL particles which is most important.

Diet {#s13}
====

Core recommendations for the dietary management of dyslipidemia focus on dietary fat intake, particularly the amounts of saturated and trans-fat, and on cholesterol and caloric intake as well as eating a wide variety of healthy foods \[[@bib-042],[@bib-043]\]. In addition, a number of supplements and functional foods show promise and continue to be investigated.

Omega-3 poly-unsaturated fatty acids {#s14}
====================================

The omega-3 polyunsaturated fatty acids (PUFAs) are a group of three essential fatty acids found in oily fish (eicosapentaenoic acid \[EPA\], docosahexaenoic acid \[DHA\]) and in plant seeds and oils (α-linolenic acid \[ALA\]). EPA, DHA, and to a lesser extent ALA have been shown to be effective in reducing serum triglycerides \[[@bib-043]\]. They also appear to exert anti-atherogenic effects via the inhibition of thromboxane and pro-inflammatory cytokine production, leading to reduced platelet aggregation and vascular inflammation \[[@bib-044]\].

The RCT data concerning omega-3 PUFAs are inconsistent. Among trials in 2002, the GISSI-Prevenzione group \[[@bib-045]\] reported effects of omega-3 PUFAs on mortality in post-MI patients. A daily dose of 1 g/day of PUFA was associated with an early and sustained reduction in risk of sudden death. Triglyceride concentrations were reduced slightly but significantly compared to controls; however, there was no significant overall change in total and LDL-cholesterol concentrations. The authors questioned whether the outcomes (particularly at a lower dose of 1 g/day) could be attributable to anti-arrhythmic and anti-fibrillatory effects, via effects on membrane channels, which have been seen in animal studies.

The very large open-label interventional JELIS trial \[[@bib-046]\] studied the concomitant use of pravastatin or simvastatin with highly purified EPA (1.8 mg/day) against statin alone in 18,645 patients. The EPA group had a significant 19% reduction in fatal CHD events, although there was no effect on CHD or sudden cardiac death. LDL-cholesterol concentrations were not significantly changed by EPA, again suggesting effects via triglycerides or other mechanisms. It should be noted that the trial was undertaken in a Japanese population with a high background of dietary omega-3 intake, a potential confounding factor.

A more recent placebo-controlled RCT undertaken by the Risk and Prevention Study Collaborative Group \[[@bib-047]\] found that supplementation of 1 g combined EPA and DHA reduced triglyceride concentrations significantly (−28.2 ± 1.3 mg/dL vs. −20.1 ± 1.3 mg/dL, *P* \< 0.001), but overall had no favorable effect on clinical events in subjects with high cardiovascular risk but no previous MI. Other recent trials have also shown neutral results. These include the Alpha Omega Trial, which investigated 400 mg EPA-DHA and 2 g ALA daily in post-MI survivors \[[@bib-048]\]. However, there were marginal benefits in non-statin users.

The inconsistencies in clinical trial data quite possibly relate to the dose of omega-3 PUFAs investigated and whether or not this was on a background of statins. Larger doses of these supplements may have a particular role as one of the options in individuals who cannot tolerate statins.

At this time, the European Society of Cardiology \[[@bib-043]\] recommend an intake of at least 2-3 servings of fish per week for CVD prevention and suggest that supplementation of 2-3 g/day of EPA-DHA may be useful for reduction of triglycerides.

Mediterranean diet {#s15}
==================

The Mediterranean diet is distinguished by a regular intake of vegetables, fruit, whole grains, mono-unsaturated fats, fish, nuts, and legumes and reduced consumption of red meat and high-fat dairy products \[[@bib-049]\]. Characteristically, it provides a high intake of unsaturated fat and a low amount of saturated and trans-fat. Studies to date show promise for this diet in reducing cardiovascular risk factors and CVD events. Extended follow-up of the Lyon Heart Study \[[@bib-050]\] reported that a Mediterranean-type diet was associated with a large reduction in non-fatal MI and cardiac death (1.24 and 4.07 per hundred patients per year after 46 months in the intervention and control groups, respectively). Higher plasma ALA levels were also found to improve prognosis, although the same was not determined for EPA and DHA.

A 2011 meta-analysis of six trials found that the Mediterranean diet was more effective than a low-fat diet in reducing cardiovascular risk factors long-term \[[@bib-051]\]. A similar result was found by a meta-analysis of 50 studies involving 534,906 individuals, assessing effects of the diet on components of the metabolic syndrome \[[@bib-049]\]. A recent study in a Danish cohort found that adherence to the Mediterranean diet was associated with reduced all-cause mortality and cardiovascular events and mortality, but not stroke \[[@bib-052]\].

Recently, the Spanish PREDIMED \[[@bib-053]\] primary prevention trial reported a reduced risk of cardiovascular events in patients with a high CVD risk, who ingested a Mediterranean diet supplemented with either mixed nuts or extra virgin olive oil.

In the GISSI-Prevenzione trial, moderate wine intake, which is also characteristic of the Mediterranean diet, was associated with no increased risk and a potential reduced likelihood of CVD events in patients with a recent MI \[[@bib-054]\].

European guidelines \[[@bib-055]\] discuss the emerging evidence of the Mediterranean diet pattern and recommend a healthy diet for CVD prevention, which includes intake of fish, whole grains, fruit, vegetables, and alcohol in moderation and reduced saturated and trans-fat intake.

Phytosterols and dietary fiber {#s16}
==============================

Phytosterols decrease serum cholesterol and LDL-cholesterol concentrations by inhibiting cholesterol absorption \[[@bib-056]\]. The International Atherosclerosis Society (IAS) and European Society of Cardiology (ESC) \[[@bib-042],[@bib-043]\] state that an intake of 1-2 g/day may be useful for reduction of LDL-cholesterol. Dietary fiber is also a key preventive measure for lowering LDL-cholesterol, with the IAS \[[@bib-042]\] recommending 10-25 g/day of soluble fiber alongside phytosterols.

Other lifestyle factors {#s17}
=======================

Smoking cessation is fundamental in reducing CVD risk at an individual and population level. The IAS \[[@bib-042]\] also recommends an upper alcohol limit of 2 servings per day for men and 1 for women, aerobic activity for 30 minutes daily, at least 5 days per week, and maintenance of body mass index (BMI) and waist circumference within healthy ranges.

Smoking cessation, physical activity, weight reduction, and alcohol modification can increase HDL-cholesterol concentrations \[[@bib-057],[@bib-058]\]. Alcohol modification can also have an impact on triglycerides \[[@bib-043]\].

The Look AHEAD research group recently reported a study of 5,145 patients with type 2 diabetes and a BMI of at least 25 kg/m^2^ and showed that a multiple lifestyle intervention consisting of exercise, group meetings, and dietary restriction resulted in significant weight loss and reduction in cardiovascular disease risk factors over 4 years \[[@bib-059]\]. However, the trial was subsequently terminated early after a median of 9.6 years, on the basis of futility, when 13.5-year follow-up was planned investigating the effects on CVD events \[[@bib-060]\].

Implications for clinical practice {#s18}
==================================

A major outstanding challenge is how best to implement use of evidence-based therapies in clinical practice, particularly statins. Observational data in Europe \[[@bib-061]\] and other countries throughout the world \[[@bib-062]\] have shown poor concordance with proven therapies, including statins in CHD patients. Persistence with statins is even less in those who are apparently healthy but in whom they are considered indicated. If therapies are applied particularly to those at highest risk, they are most cost-effective. In this case, supportive systems of care will often be necessary to facilitate translation of RCT evidence to improve outcomes in usual patients. Another important aspect is effective communication of the risk of future events to susceptible individuals. Among newer approaches are the concepts of heart or vascular age \[[@bib-063]\] and of lifetime or modifiable risk, particularly in relatively younger individuals who may be disadvantaged by absolute (global) risk assessment when they have relatively high modifiable risk factor levels. This is because advancing age is its major driver of risk in absolute risk algorithms such as derived from the Framingham Heart Study \[[@bib-064]\] and the SCORE project \[[@bib-063]\].

A final comment concerns lifestyle. Atherosclerosis is a largely preventable process, which is driven particularly by behavioral and lifestyle factors. Adherence to a healthy lifestyle, extending beyond nutrition alone, has been shown to improve outcomes whether or not drug therapies, including those targeting dyslipidemia, are being used. Different levels of government can impact enormously by enacting appropriate legislation and promoting supportive environments and other important population-wide strategies.
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